Clinical Trials Logo

Inflammation clinical trials

View clinical trials related to Inflammation.

Filter by:

NCT ID: NCT04517552 Active, not recruiting - Alzheimer Disease Clinical Trials

Investigation of Inflammation Using [C-11]-CS1P1

CS1P1
Start date: November 2, 2020
Phase:
Study type: Observational

There is a compelling need for a noninvasive imaging approach to measure S1P1 in both preclinical models of diseases and humans. PET measures of S1P1 expression is critical for elucidating the pathophysiological roles of S1P1 in neuroinflammation and neurodegeneration. The relevance of S1P1 in clinical disease has become readily apparent with the FDA approval of the S1P1 modulator FTY720 (fingolimod) for treating relapsing-remitting MS (RR-MS). MS is a chronic autoimmune, inflammatory disease caused by lymphocytic infiltration that leads to demyelinating neurodegenerative disease.

NCT ID: NCT04497727 Active, not recruiting - Gut Inflammation Clinical Trials

Gut Organoid Study

Start date: March 5, 2021
Phase:
Study type: Observational

The study will compare basic properties of gut epithelia of hypertensive and normotensive reference subjects. The study will determine if there are fundamental differences in the gut epithelium in hypertension compared to normotension.

NCT ID: NCT04479514 Active, not recruiting - Pediatric Cancer Clinical Trials

Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.

NCT ID: NCT04456673 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NOTUS
Start date: July 6, 2020
Phase: Phase 3
Study type: Interventional

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by - Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on - Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo - Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) - Pre-bronchodilator FEV1 over 52 weeks compared to placebo - Lung function assessments - Moderate and severe COPD exacerbations - To evaluate safety and tolerability - To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)

NCT ID: NCT04444128 Active, not recruiting - Heart Failure Clinical Trials

IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION

IMPReSSION
Start date: November 15, 2016
Phase:
Study type: Observational [Patient Registry]

Magnetic properties of myocardial tissue change in the presence of disease. This is detectable in the change of rate of magnetic relaxation, and measurable by T1 and T2 mapping using cardiovascular magnetic resonance (CMR). These markers provide novel quantifiable imaging measures for myocardial tissue characterisation. Despite similar principles, the measurements differ considerably between different sequences, vendors and field strengths, yielding a necessity to establish robust sequence-specific normal ranges, diagnostic accuracy, relationships with clinical characteristics, cardiovascular risk factors, routine cardiac imaging parameters, and prognosis. A further unknown relates to separation between healthy myocardium and subclinical disease in subgroups of patients with suspected cardiac involvement. Examples include patients with possible inflammation, such as in patients with a recent COVID-19 infection or vaccination. Anticipated recruitment of a total of 3000 subjects, with 1500 subjects per field strength (1.5 and 3.0 Tesla).

NCT ID: NCT04444102 Active, not recruiting - Inflammation Clinical Trials

The Acute Impact of Yoga-based Stretching on Inflammation and Its Resolution

Start date: January 30, 2020
Phase: N/A
Study type: Interventional

The goal of this study is to explore the impact of two types of yoga-based body stretching (mild and intense) on dynamic changes of Systemic Inflammatory Cytokines (SICs) and Specialized Pro-resolving Mediators (SPMs) in yoga-naïve subjects.

NCT ID: NCT04399135 Active, not recruiting - Periodontitis Clinical Trials

Accuracy of Pulp Sensibility Test on Teeth With Deep Periodontal Pocket

Start date: February 25, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the accuracy of pulp test in teeth presenting with deep periodontal pocket. The null hypothesis is no significant effect of periodontitis on the accuracy of pulp test.

NCT ID: NCT04392544 Active, not recruiting - Cystic Fibrosis Clinical Trials

Intestinal Inflammation in CF Patients

Start date: September 11, 2018
Phase:
Study type: Observational

Cystic Fibrosis (CF) is a disease that affects salt and water transport in multiple organs. Many CF patients suffer from abdominal pain and this could be due to intestinal inflammation. However, so far we do not know how many of the CF patients actually do have intestinal inflammation when looking at intestinal specimens. There is a proven connection between chronic inflammation and developing colorectal cancer and over the years more CF patients are developing colorectal cancer. Thus, it becomes increasingly important to look for the presence of intestinal inflammation in CF patients since early treatment may improve their symptoms and reduce the risk for colorectal cancer.

NCT ID: NCT04375982 Active, not recruiting - Inflammation Clinical Trials

Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests

NOVEL-3
Start date: April 20, 2020
Phase: N/A
Study type: Interventional

A Multicenter Study Conducted to Evaluate the Agreement between Fingerstick Whole Blood, Venous Whole Blood and Plasma Determined on the LumiraDx Point of Care D-Dimer and Point of Care CRP Tests to Results on the Reference Analyzer

NCT ID: NCT04343469 Active, not recruiting - Morbid Obesity Clinical Trials

Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, and Activation of Central Reward System

BARIBRAIN
Start date: February 11, 2019
Phase: N/A
Study type: Interventional

Background: The investigators have found that obesity and insulin resistance result in significantly increased brain insulin-stimulated glucose uptake, whereas in every other tissue glucose uptake is lower in the obese compared to lean individuals. One possible explanation to this could be central inflammation and activation of brain glial cells, which has been shown to occur in animal models of obesity. Aims: The objective of this study is to investigate whether there is brain inflammation in human obesity, and whether weight loss following bariatric surgery decreases brain inflammation. Methods: A total of 60 morbidly obese subjects, assigned for Roux-en-Y gastric bypass or for sleeve gastrectomy according to routine treatment protocols will be recruited for this study. A control group of 30 healthy subjects will also be recruited. The following studies will be performed to patients and healthy subjects: 1) structural MRI and MRS, 2) functional MRI, 3) PET imaging of cerebral inflammation and astrocyte activation using [11C]-PK11195, 4) measurement of whole-body and tissue insulin sensitivity by combining hyperinsulinemic, euglycemic clamp with [18F]-FDG-PET, 5) neuropsychological testing. The study procedures will be repeated for the morbidly obese 6 months postoperatively.